Has Convalescent Plasma Therapy Hesitancy Increased COVID-19 Mortality?

 

 Permissions and Reprints

Abstract

We bring to you our viewpoint and a snapshot of the journey of convalescent plasma therapy (CPT) in the management of ongoing coronavirus disease 2019 (COVID-19) pandemic. We also discuss how best to use the updated data on this important treatment option and maximize benefit for our patients, thereby saving lives, especially in resource constraint settings.

Publication History

Article published online:
21 August 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

• References

• 1 Available at: https://www.youtube.com/watch?v=SaaeJC1qAUM Accessed May 9th, 2021
• 2 Parikh PM, Joshi S, Gulia A. Resurgence of COVID-19 in India—challenges and solutions. Int J Med Sci 2021; 73: 70-74
  Google Scholar
• 3 Available at: https://www.google.com/search?q=convalescent+plasma+therapy+covid-19. Accessed May 9th, 2021
• 4 Available at:https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=convalescent+plasma+therapy+covid-19&btnG=. Accessed May 9th, 2021
• 5 Available at:https://pubmed.ncbi.nlm.nih.gov/?term=convalsecent+plasma+therapy+covid-19+202. Accessed May 9th, 2021
• 6 Li L, Zhang W, Hu Y. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020; 324 (05) 460-470
  CrossrefPubMedGoogle Scholar
• 7 Simonovich VA, Burgos Pratx LD, Scibona P. et al. PlasmAr Study Group. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 2021; 384 (07) 619-629
  CrossrefPubMedGoogle Scholar
• 8 COVID-19 resources. Available at: https://www.hematology.org/covid-19/covid-19-and-convalescent-plasma. Version 7.0; last updated March 23, 2021. Accessed May 9th, 2021
• 9 Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial. BMJ 2020; 371: m3939
  CrossrefPubMedGoogle Scholar
• 10 Gundavda KK, Parikh PM. Convalescent plasma therapy for COVID-19 still has the potential to save lives—the ICMR PLACID study dissected. Int J Molecular & Immuno Oncology 2020; 6: 47-49
  CrossrefGoogle Scholar
• 11 Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis. J Med Virol 2021; 93 (02) 1111-1118
  CrossrefPubMedGoogle Scholar
• 12 Pau AK, Aberg J, Baker J. et al. Convalescent plasma for the treatment of COVID-19: perspectives of the National Institutes of Health COVID-19 treatment guidelines panel. Ann Intern Med 2021; 174 (01) 93-95
  CrossrefPubMedGoogle Scholar
• 13 Casadevall A, Dragotakes Q, Johnson PW, et al. Convalescent plasma use in the United States was inversely correlated with COVID-19 mortality: did plasma hesitancy cost lives? MedRxiv doi: https://doi.org/10.1101/2021.04.07.21255089 /prpt
• 14 Salazar E, Christensen PA, Graviss EA. et al. Significantly decreased mortality in a large cohort of coronavirus disease 2019 (COVID-19) patients transfused early with convalescent plasma containing high-titer anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein IgG. Am J Pathol 2021; 191 (01) 90-107
  CrossrefPubMedGoogle Scholar
• 15 Boonyaratanakornkit J, Morishima C, Selke S. et al. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. J Clin Invest 2021; 131 (03) e144930
  CrossrefPubMedGoogle Scholar
• 16 Li L, Tong X, Chen H. et al. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation. Transfusion 2020; 60 (08) 1765-1772
  CrossrefPubMedGoogle Scholar
• 17 Jungbauer C, Weseslindtner L, Weidner L. et al. Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations. Transfusion 2021; 61 (01) 12-16
  CrossrefPubMedGoogle Scholar
• 18 Anand SP, Prévost J, Nayrac M. et al. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. Cell Rep Med 2021; 2 (06) 100290
  CrossrefPubMedGoogle Scholar
• 19 Alsharidah S, Ayed M, Ameen RM. et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study. Int J Infect Dis 2021; 103: 439-446
  CrossrefPubMedGoogle Scholar
• 20 Libster R, Pérez Marc G, Wappner D. et al. Fundación INFANT–COVID-19 Group. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med 2021; 384 (07) 610-618
  CrossrefPubMedGoogle Scholar
• 21 Budhiraja S, Dewan A, Aggarwal R. et al. Effectiveness of convalescent plasma in Indian patients with COVID-19. Blood Cells Mol Dis 2021; 88: 102548
  CrossrefPubMedGoogle Scholar
• 22 Parikh P, Singh R. Hot race for COVID-19 vaccines—light at the end of the tunnel just got brighter. Int J Mol Immuno Oncol 2021; 6 (01) 1-3
  CrossrefGoogle Scholar
• 23 Raja T, Parikh PM, Ghafur A. et al. South Asian Declaration—consensus guidelines for COVID-19 vaccination in cancer patients. South Asian J Cancer 2021;In press
• 24 Available at: www.amberhealth.in. Accessed May 9, 2021
• 25 Available at: https://www.youtube.com/watch?v=VnKiviXr59M. Accessed May 9, 2021